

PATENTS

Recent patent applications in the area of toxicology

Patent #	Subject	Assignee	Author	Publication date	Status*
WO 9639184	Treating patients at risk of systemic inflammatory response syndrome with antagonist of parathyroid hormone-related protein to reduce or delay toxic effects of endotoxin or cytokine.	Univ of California	Feingold KR, Funk J, Grunfeld C	05/30/96	A1
WO 9639168	Stimulating an immune response to increase high-density lipoprotein, avoiding repeated administration of toxic drugs to lower cholesteryl ester transfer protein levels.	Immune Response Corp Carlsbad, CA	Brostoff SW, Carlo DJ, Kwoh DY	06/05/96	A1
WO 9639146	Aqueous non-ototoxic compositions containing ciprofloxacin, hydrocortisone, and polyvinyl alcohol are nonirritating and nonsensitizing. Useful in treatment of otitis externa or otitis media.	Bayer Corp West Haven, CT	Goldman D, Purwar S	06/05/96	A1
WO 9639143	Pharmaceutical formulations, containing highly lipophilic camptothecin derivatives and <i>N</i> -methyl-pyrrolidin-2-one, have reduced toxicity and better patient acceptance.	BioNumerik Pharmaceutical Inc San Antonio, TX	Haridas K, Hausheer FH, Murali D, Reddy DG	06/04/96	A1
WO 9639137	New Ras farnesyl transferase inhibitors have improved activity and reduced toxicity. Useful for treating cancers and neurological tumors.	Merck & Co Inc Whitehouse Station, NJ	Anthony NJ, Desolms SJ, Bergman JM, Dinsmore CJ, Gomez RP, Mactough SC, Solinsky KM, Williams TM	06/03/96	A1
GB 2301820	New carbapenem derivatives are antibacterial agents. Used to treat medical or dental equipment, paper-mill water, paints, and are nontoxic.	Merck & Co Inc Whitehouse Station, NJ	Greenlee ML, Laub JB	05/29/96	A
EP 748627	Treatment of benign prostatic hyperplasia using melatonin agonists, particularly <i>N</i> -acyl-5-hydroxy-tryptamine derivatives, without toxicity at treatment doses.	Eli Lilly & Co Indianapolis, IN	Clarke DO, Jordan WH, Shipley LA	06/06/96	A2
WO 9638477	<i>B. thuringiensis</i> var. <i>thuringiensis</i> protein having cytotoxic activity—for treatment of tumors, possibly by apoptosis, and for purging bone marrow. Not toxic to normal cells.	Res Dev Found	Aggarwal BB, Padilla CR	05/31/96	A1
WO 9637219	Vaccines derived from <i>M. tuberculosis</i> major abundant extracellular proteins are easy to prepare and less toxic than conventional killed or attenuated vaccines. Useful for protecting against or treating mycobacterial infections.	Univ of California	Harth G, Horwitz MA	05/23/96	A1
WO 9637194	Stable synthetic nucleic acid delivery vehicle containing amphipathic cationic lipid conjugate. Useful as vectors for gene therapy, have low toxicity and retain transfection activity for at least 2 days after preparation.	Somatix Therapy Corp Alameda, CA	Hofland H, Sullivans SM	05/21/96	A1
WO 9636384	Gas-mixing device in, or for, a breathing system, e.g., ventilators. Has turbulence device to ensure thorough mixing of gases while reducing production of toxic by-products from exposure of gases to each other.	Univ of Florida Gainesville, FL	Blanch PB, Skimming JW	05/14/96	A1
WO9636331	Treatment of endotoxic shock in humans and animals, comprising administration of a pharmaceutically acceptable gallium compound.	Ohio State Univ Columbus, OH	Apseloff G, Gerber N, Krecic ME, Mullet DI	05/07/96	A1
WO 9635444	Peptide, reversing the anticoagulant effects of heparin, is based on protamine but has fewer positive charges for reduced toxicity.	Univ of Michigan Ann Arbor, MI	Andrews PC, Stanley JC, Wakefield TW	05/08/96	A1
WO 9535454	Packaging and producer cells for preparation of infectious virus for gene therapy. Includes sequence encoding toxic viral envelope protein under control of promoter regulatable by tetracycline, avoiding constitutive expression of the protein.	Genetic Therapy Inc, Gaithersburg, MD St Jude Children's Research Hospital	Grosveld GC, Nenhuis AW, Vanin EF, Yang Y	09/06/95	A1

Source: Derwent Information, McLean, VA. *The patents in the table are pending. The status of each application is slightly different from country to country. For further details, contact Derwent scientific and patent information at Derwent North America, 1420 Spring Hill Road, Suite 525, McLean, VA 22102. Tel: 1 (800) DERWENT (info@derwent.com).